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Summary: Symposium on Lymphocyte Activation
Editor's Note:
The International Society of Nephrology is currently sponsoring a series entitled "Forefronts in Nephrology," under the direction of
Professor G. Giebisch. On October 11—14, 1989, a Symposium on Lymphocyte Activation was held on Les Embiez island, France, and was
chaired by Professor Jean-Fran cois Bach (Paris, France). The following is a summary of the Symposium, prepared by Dr. Bach.
A three-day meeting, the fourth in the "Forefronts in
Nephrology" series, was held on Les Embiez island in front of
Toulon on the Mediterranean sea, October 11 to 14, 1989.
Seventy participants enjoyed a very stimulating series of lec-
tures and discussion sessions dealing with the topics of immu-
nology (T cell receptor, MHC antigen interaction, immunoreg-
ulation, cytokines) and immuno-nephrology (cytokines and
lymphocyte activation in uremic and hemodialyzed patients,
phenotype, repertoire and function of cells infiltrating renal
ailografts, aberrant expression of MHC antigen in autoimmune
lupus and diabetes, idiotype network in systemic lupus and
interstitial nephritis, monoclonal anti-T cell antibodies, etc.).
Interstingly, in the spirit of ISN Forefront Symposia, the
attendance included an equilibrated balance of nephrologists,
immunonephrologists, and immunogists. Several major points
emerged, notably the importance of studying the B and T cell
repertoire in autoimmune and allogeneic reactions, as well as
the interest of new explanations for lymphocyte disturbances
observed in hemodialyzed patients, which could probably lead
to a final understanding of the onset of amyloidosis in such
patients and hopes for more selective and specific immuno-
intervention.
All participants agreed that, in addition to the new informa-
tion provided, the meeting illustrated the liveliness of the
immunological approach in nephrology and the need for future
meetings of this type. They were all grateful to ISN to have
permitted such an opportunity.
T cell receptor
The elucidation of the nature and of the genetic organization
of the T cell receptor opened new perspectives in the study of
cell-mediated immunity. Two lectures, by T. Mak (Toronto)
and B. Malissen (Marseille), provided a unique update on the
two types of T cell receptor: the c43 and the y.5 heterodimers.
Particular emphasis was made on the respective functions of
the two receptor types. Arguments were presented suggesting
that the yb receptor is used early in ontogenesis and may exert
a regulatory function on af3+ T cells.
The TCR repertoire of T cells infiltrating renal allografts was
discussed by J.P. Soulillou (Nantes). Cells were recovered from
rejected kidneys and grown in culture in the presence of
interleukin 2. No obvious bias in the T cell repertoire was
evidenced. One may assume, however, that the situation is
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different at the initiation of rejection where a more restricted T
cell response operates. The observation made in several au-
toimmune diseases and some alloimmune responses that se-
lected V/3 genes are used suggest the possible restriction of V
gene usage by alloreactive T cells. It is indeed a crucial problem
to know whether T cells use a single or a limited number of V
genes in allograft rejection or autoimmune diseases, as they
have been shown to do in experimental allergic encephalomy-
elitis and in the response to some defined antigens. It is
important on a theoretical basis. It could also be important from
a therapeutic viewpoint, with the potential use of selective
anti-V13 monoclonal antibodies permitting an avoidance of the
over-immunosuppressive states often observed with anti-pan T
cell antibodies.
Regulatory T cells. Role in diabetes, interstitial nephritis and
mercury-induced membranous nephropathy
The existence of suppressor T cells has recently been ques-
tioned. This denial is based on the absence in the major
histocompatibility complex of the I-J locus postulated to control
suppressor T cell function, as well as by the absence of a
specific phenotypic marker for suppressor cells (CD8+ cells
include other cell types and some suppressor phenomena are
mediated by CD4+ T cells, more particularly the CD 45R+,
2H4+ subset). It remains, however, that the existence of a T
cell-mediated suppression has been well established in a num-
ber of immunopathological models, notably interstitial nephritis
in the kd/kd mouse and type I diabetes mellitus in NOD mice.
E. Neilson reported data in favor of the existence of suppres-
sor T cells with antigen specificity and idiotype positive recep-
tors. New results have been presented indicating the existence
of a suppressor factor whose chemical nature and antigen
specificity remain to be determined.
Direct evidence for the existence of suppression T cells in the
control of autoimmune diabetes mellitus in NOD mice was
presented by J.F. Bach (Paris). The existence of such a sup-
pressor control is indicated by the acceleration of disease
course by thymectomy and cyclophosphamide treatment. The
direct demonstration of these suppressor T cells has been
obtained in transfer experiments. Spleen cells from female
NOD mice transfer diabetes in irradiated healthy NOD male
mice. This transfer is abrogated by previous transfer of spleen
cells from non-diabetic male mice. Protective (suppressor) cells
are T cells with the CD4 phenotype. Such cells may be
activated by in vivo treatment with anti-class II monoclonal
antibodies.
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In the same vein, P. Druet (Paris) described an interesting
model of immune dysregulation induced by mercury chloride
injections in the BN rat. This treatment leads to the onset of
membranous nephropathy. Arguments have been collected to
indicate that the autoimmune response against tubular antigens
as well as the immune complex deposition that are character-
istic of this experimental nephritis are secondary to polyclonal
B cell activation by mercury.
Aberrant expression of MHC products in autoimmunity
The nature of the triggering events that lead to autoimmunity
is still essentially unknown. A current hypothesis holds that
autoantigens may become immunogenic when they are associ-
ated with aberrantly increased expression of class II MHC
products by the autoantigen bearing cells. Such aberrant
expression of MHC antigens has indeed been observed in
several human autoimmune diseases: Graves' disease, type I
diabetes, primary biliary cirrhosis, etc. The problem remains,
however, to determine whether this aberrant expression of
MHC antigens is primary (induces the immune response) or
secondary (to the immune response elicited by other mecha-
nisms). A lively discussion took place on this central topic of
autoimmunity.
The "inventor" of the theory, F. Bottazzo (London) pre-
sented several arguments in favor of a primary role, notably the
consistency of aberrant MHC class II expression in early stages
of several autoimmune diseases, and in vitro induction of this
aberrant expression by cytokines (IFNy and TNFa).
He was challenged by C. Benoist (Strasbourg) who described
experiments in which mice made transgenic for 13 cell-directed
MHC antigens (class II) did not show diabetes, a finding
suggesting that aberrant MHC expression on f3 cells even during
fetal development is not sufficient to induce autoimmunity.
Additionally, V. Kelley (Boston) reported the aberrant class
II and increased class I MHC antigen expression in the kidneys
of lupus mice, without chosing, however, between the primary
and secondary nature of these observations.
Cytokines in hemodialyzed patients
C. Dinarello (Boston) discussed the influence of dialysis on
interleukin 1 production by human mononuclear cells.
There is ample clinical evidence supporting the contribution
of IL-l in hemodialysis (HD)-induced pathology; several fac-
tors could be responsible for abnormal IL-i production, namely
dialysis membrane monocyte interaction, presence of bacterial
pyrogen in the dialysate, and serum factors such as complement
components which are generated during HD treatment. Data
were shown indicating that significant IL-I activity can be
detected in the plasma on long-term HD patients treated with
regenerated cellulosic membranes.
In vitro, it was also shown that regenerated cellulose (RC)
and polyacrilonitrile (PAN) membrane can induce IL- 1 produc-
tion by human mononuclear cells (MNC) in the absence of
endotoxin and complement. The PAN membrane induces sig-
nificantly more IL-i than the RC, but this may be masked by the
fact that PAN binds IL-i. In a closed-loop dialysis circuit, in the
presence of plasma, IL-i induces various factors to pass into
the blood compartment of a dialysis system challenged with
bacterial pyrogen. This in vitro MNC-IL-l production provides
a reliable and relevant assay to determine dialysis membrane
permeability under the influence of pyrogens.
In vitro addition of indomethacin to MNC cultures of normal
subjects without medication increases IL-l/3 production. In
vivo production of IL-lJ3 is significantly increased in normal
volunteers given a cyclo-oxygenase inhibitor (aspirin, ibuprofen
or Naproxen) during the previous week as compared to subjects
without medication. When MNC from both groups were stim-
ulated in the presence of indomethacin, the production of IL-i
was increased in the group without medication, but was statis-
tically unchanged in the group taking cyclooxygenase inhibi-
tors.
Lastly, C. Dinarello presented conclusive evidence showing
that lipid A is the main portion of LPS responsible for induction
of both extracellular and cell-associated IL-i, and that specific
activation and/or binding mechanisms are involved in stimula-
tion of cells with LPS and lipid A.
B. Descamps-Latscha (Paris) presented results obtained in
the study of the respective influence of uremia and hemodialysis
(HD) on circulating IL-i and TNFa. IL-l and TNFa were
determined in the plasma of long-term hemodialysis (HD)
patients and uremia (UR) patients undergoing their first dialysis
session using either cuprophan or PAN membrane equipped
dialyzers. In long-term HD patients, plasma IL-i and TNFa
levels were significantly increased compared to their levels in
normal subjects. During a single dialysis session, a significant
increase in IL-i but not in TNFa was observed. In not yet
dialyzed UR patients, IL-i plasma levels did not differ from
those observed in normal subjects. By contrast, TNFa was
found significantly increased although less than in long-term
HD patients. During the first dialysis session, no significant
increase was observed in the levels of either monokine. Lastly,
regardless of the group of patients, no significant influence of
the dialysis membrane could be detected, suggesting that the
observed changes are not exclusively secondary to the activa-
tion of complement. All together, these results suggest that the
passage of the blood through the extracorporeal dialysis circuit
triggers the secretion of IL-i and further exacerbates that of
TNFa by monocytes. The presence of increased TNFa in the
plasma of first dialysis UR patients suggests that factors unre-
lated to dialysis contribute to the activation of monocytes in
these patients. Lastly, the concomitant presence of IL-l and
TNFa in the plasma of long-term HD patients could be respon-
sible for some of the clinical features observed in these patients,
and provides strong evidence favoring the concept that HD can
be assimilated to a recurrent acute-phase inflammatory re-
sponse.
S. Meuer (Zurich) presented evidence of a selective blockade
of the antigen-receptor mediated pathway of T cell activation in
patients showing unpaired primary immune responses second-
ary to chronic renal failure.
Unresponsiveness to hepatitis B vaccine correlates with a
blockade of the 13-Ti antigen receptor-mediated mode ofT cell
activation, whereas the Ti 1 pathway remains unaffected. Re-
duced I cell activity is a consequence of monocyte failure.
Monocyte function with regard to T cell receptor activation is
not restricted to insufficient IL-i production but also involves
the subsequent failure to produce IL-2. This view is supported
by the demonstration that addition of IL-2 fully reconstituted
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the abnormal proliferative responses of non-responder lympho-
cytes after antigen-receptor triggering.
Based on these observations, S. Meuer suggested that addi-
tion of IL-2 during vaccination may represent a useful strategy
to circumvent the non-responder state in vivo in hemodialyzed
subjects and perhaps improve the overall immunodeficiency
known to exist in patients with chronic renal failure.
The therapeutic use of monoclonal antibodies and cytokines
H. Waldmann (Cambridge) discussed the in vivo use of
murine and humanized monoclonal anti-T cell antibodies. Anti-
CD4 antibodies can promote the induction of tolerance towards
transplantation antigens. There is no requirement for CD8 cells
for the generation of tolerance, nor is there any evidence of
transferable suppression. Tolerance can be maintained indefi-
nitely if the antigen is reinjected every five weeks without
further need for anti-CD4 MoAb therapy, the so-called "rein-
forcement phenomenon." Importantly, there is no need for
depletion of CD4+ cells to induce the tolerance. Similar data
were reported for a non-depleting MoAb to another T cell
surface adhesion molecule LFA-l. Lastly, tolerance may be
induced towards minor histocompatibility antigens (Mls). Tol-
erance is best achieved when one associates anti-CD4 and
anti-CD8 MoAbs or their F(ab')2 fragments (which do not
induce any cellular depletion). H. Waldmann also discussed the
important issue of humanized MoAbs, especially of CAM-
PATH-lH, a genetically reshaped human IgGI monoclonal
antibody. CAMPATH-l is an IgGl directed towards an antigen
abundantly expressed on virtually all lymphoid cells and mono-
cytes, but not on other cell types. The IgG2b rat CAMPATH-
1G is the most actively depleting anti-T cell MoAb in vivo,
probably because it binds to human Fc receptors and activates
complement. CAMPATH-1G is very effective in the treatment
of lymphoid malignant disorders. Unfortunately, its use is
hampered by the rapid occurrence of a neutralizing antiglobulin
response. In order to circumvent this major side effect, a
reshaped CAMPATH-1H obtained by molecular engineering
was constructed. This MoAb associates the hypervariable
regions of the rat antibody with normal human immunoglobulin
constant region. The chimeric antibody still exhibits the same T
cell depleting and complement activation properties of the rat
antibody. Four patients suffering from either non-Hodgkin
lymphomas or from severe autoimmune diseases (rheumatoid
arthritis) were treated with the antibody. Results show that in
addition to being apparently effective in treating the disease, the
MoAb did not induce any serologically detectable antibodies.
The results are encouraging but remain to be confirmed. Fi-
nally, H. Waldmann presented very recent data dealing with the
effect of graft perfusion with two rat anti-human CD45 mono-
clonal antibodies (anti-pan leucocytes) on the incidence of
kidney allograft rejection. Seventy-seven patients were ran-
domized to receive first cadaver kidney allografts perfused
either with a pair of CD4S monoclonal antibodies in an attempt
to reduce the immunogenicity of passenger leucocytes (that are
potent antigen presenting cells) or with human albumin solu-
tion. Patient and allograft survivals were similar in both groups,
but, rejection episodes were recorded in 18% of the patients
treated with the MoAbs, whereas 63% of the albumin perfused
kidneys experienced rejection episodes.
L. Chatenoud (Paris) discussed the in vivo immunologic
effect of anti-T cell receptor (CD3/Ti) antibodies in human renal
allograft recipients. OKT3, a murine anti-human CD3 monoclo-
nal antibody is one of the most potent and widely used
immunosuppressive agent in organ transplantation. One major
side effect associated with the in vivo use of OKT3 is the
spontaneously reversible, systemic clinical reaction that invari-
ably follows the first injections of this MoAb. This systemic
reaction mainly includes chills, headache, pyrexia, vomiting,
diarrhea, tachycardia, myalgia and seldom meningismus and
pulmonary edema. To test the hypothesis that this OKT3
induced reaction relates to in vivo cell activation leading to bulk
release of cytokines in the circulation, 35 renal allograft recip-
ients receiving OKT3 were studied. Blood samples were col-
lected before and at one and four hours following the first,
second and third OKT3 injections. Results showed that the first
injection induces a sharp increase in circulating tumor necrosis
factor (TNFa) and interferon gamma (INF7) levels peaking
respectively one hour and four hours after the OKT3 injection.
IL-2 peaking four hours after the injection was detected only in
the sera of three patients who did not receive steroids. Serum
cytokine levels were back to pretreatment values by 15 to 20
hours. This cytokine release fully confirms the anti-CD3 in vivo
induced cell activation and parallels the clinical reaction that is
as cytokine release self-limited. Although not lethal in most
instances, this reaction is highly disabling to the patients and
has up to now prevented the extension of its use to clinical
settings other than transplantation. To get further insights into
the pathophysiology of the reaction and to test different thera-
peutic strategies trying to circumvent it, a murine model using
the 145 2C1 I MoAb that is a hamster anti-murine CD3 MoAb
was set up. Mice receiving this MoAb presented, like human
patients, both a severe physical reaction associating hypomo-
tility, hypothermia, diarrhea and piloerection, and paralleling
this disease a bulk release of several cytokines (mainly TNF,
IL-2, IFN7, IL-3 and IL-6) detected in sera drawn 90 minutes,
4, 8 and 24 hours after OKT3 injection. Importantly, severe
anatomopathological lesions affecting lungs and liver were also
obvious 24 hours after the injection. Different mouse strains,
NZW, C3H/HeJ and CBAIJ, receiving the same anti-CD3 dose
reacted differently. These data are in keeping with a different
pattern of cytokine release and points to the importance of
synergisms existing among these cytokines and to the pivotal
role played by some of these molecules, but not all, in the
induction of the disease (TNF, IFNy). Interesting and promis-
ing results indicating the beneficial effect of anti-TNF MoAb in
the prevention of the OKT3-induced reaction were presented.
T. Strom (Boston) presented an alternative approach using
IL-2-toxin conjugate. This conjugate induces selective deple-
tion and impairment of activated T cells that express a high
level of the IL-2 receptor. It is not toxic, and shows higher
activity than anti-IL-2 receptor antibodies. It has been success-
fully applied in the prevention of heart allograft rejection and
autoimmunity in lupus and diabetic mice.
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